EUVIMEDEUVIMED entdecken
Crossref

Evaluation of (2S,4S)-4-[ 18 F]FEBGln as a Positron Emission Tomography Tracer for Tumor Imaging

Yong Huang, Yajing Liu, Chengze Li, Zhongjing Li, Hualong Chen, Lu Zhang, Ying Liang, Zehui Wu iD

Molecular Pharmaceutics · 2023

DOI: 10.1021/acs.molpharmaceut.3c00544 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Molecular Pharmaceutics, 2023. Verfasst von Yong Huang und 7 weiteren Autor:innen. Beteiligte Einrichtung: Department of Nuclear Medicine, National Cancer Center, National Clinical Research Center for Cancer, Cancer Hospital & Shenzhen Hospital, Chinese Ac…. Hauptthemen laut MEDLINE: Brain Neoplasms, Lung Neoplasms, Glioma. Die Arbeit wurde bisher 6-mal zitiert (Crossref) und nennt 43 Literaturangaben. Gefördert von: National Cancer Center, Peking Union Medical College, Chinese Academy of Medical Sciences.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Glutamine metabolism-related tracers have the potential to visualize numerous tumors because glutamine is the second largest source of energy for tumors. (2S,4S)-4-[18F]FEBGln was designed by introducing [18F]fluoroethoxy benzyl on carbon-4 of glutamine. The aim of this study was to investigate the pharmacokinetic properties and tumor positron emission tomography (PET) imaging characteristics of (2S,4S)-4-[18F]FEBGln in detail. The biodistribution results of nude mice bearing MCF-7 tumor showed that (2S,4S)-4-[18F]FEBGln had high initial tumor uptake, and a fast clearance rate, resulting in a high tumor-to-muscle ratio at 30 min postinjection. There was no obvious defluorination in vivo. The micro-PET-CT imaging results of (2S,4S)-4-[18F]FEBGln orthotopic MCF-7 tumor-bearing nude mice were consistent with the biological distribution results. Compared with (2S,4R)-4-[18F]FGln, (2S,4S)-4-[18F]FEBGln showed poor tumor retention, but its clearance in normal tissues was also fast, so it had better PET image contrast than the former. Unlike poor retention in MCF-7-bearing nude mice, (2S,4S)-4-[18F]FEBGln has good retention in NCI-h1975 and 22Rv1 tumor models. Since (2S,4S)-4-[18F]FEBGln has low uptake in normal lungs and high uptake in the bladder, it is expected to be used in the accurate diagnosis of lung cancer but cannot accurately determine prostate cancer. Consistent with the advantages of radiolabeled amino acids in the application of brain tumors, (2S,4S)-4-[18F]FEBGln accurately diagnoses U87MG glioma with higher contrast than [18F]FET and [18F]FDG, and there is a correlation between (2S,4S)-4-[18F]FEBGln uptake and tumor growth cycle. Further kinetic model analysis showed that (2S,4S)-4-[18F]FEBGln was similar to (2S,4R)-4-[18F]FGln, conforming to the one-compartment model and the Logan graphical model, and was expected to assess the size of the glutamine pool of the tumor. Therefore, (2S,4S)-4-[18F]FEBGln is expected to provide a strong imaging basis for the diagnosis, formulation of personalized plans, and efficacy evaluation of glioma, lung cancer, and breast cancer.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Brain NeoplasmsLung NeoplasmsGliomaMaleMiceAnimalsMice, NudePositron Emission Tomography Computed TomographyGlutamineTissue DistributionPositron-Emission TomographyCell Line, TumorRadiopharmaceuticals

Stichwörter der Autor:innen

(2S,4S)-4-[18F]FEBGlnglutaminepositron emission tomographytracertumor imaging

Substanzen

GlutamineRadiopharmaceuticals

Autor:innen und Institutionen

  • Department of Nuclear Medicine, National Cancer Center, National Clinical Research Center for Cancer, Cancer Hospital & Shenzhen Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College, Shenzhen 5…
  • School of Pharmaceutical Science, Capital Medical University, Beijing 100069, China.
  • Beijing Institute of Brain Disorders, Laboratory of Brain Disorders, Ministry of Science and Technology, Collaborative Innovation Center for Brain Disorders, Capital Medical University, Beijing 100069, China.

ORCID-Profile: Zehui Wu

Förderung

  • National Cancer Center
  • Peking Union Medical College
  • Chinese Academy of Medical Sciences
  • Beijing Municipal Natural Science Foundation
  • National Natural Science Foundation of China
  • Shenzhen Science and Technology Innovation Program
  • Shenzhen High-level Hospital Construction Fund
  • Medical Innovation Capability Improvement Plan of Capital Medical University

Zitieren

APA

Huang, Y., Liu, Y., Li, C., Li, Z., Chen, H., Zhang, L., Liang, Y., & Wu, Z. (2023). Evaluation of (2S,4S)-4-[ 18 F]FEBGln as a Positron Emission Tomography Tracer for Tumor Imaging. Molecular Pharmaceutics. https://doi.org/10.1021/acs.molpharmaceut.3c00544

Vancouver

Huang Y, Liu Y, Li C, Li Z, Chen H, Zhang L, et al. Evaluation of (2S,4S)-4-[ 18 F]FEBGln as a Positron Emission Tomography Tracer for Tumor Imaging. Molecular Pharmaceutics. 2023. doi:10.1021/acs.molpharmaceut.3c00544

BibTeX
@article{Huang2023,
  author = {Huang, Yong and Liu, Yajing and Li, Chengze and Li, Zhongjing and Chen, Hualong and Zhang, Lu and Liang, Ying and Wu, Zehui},
  title = {Evaluation of (2S,4S)-4-[ 18 F]FEBGln as a Positron Emission Tomography Tracer for Tumor Imaging},
  journal = {Molecular Pharmaceutics},
  year = {2023},
  doi = {10.1021/acs.molpharmaceut.3c00544}
}
Kostenlos starten →